CN1429607A - Red sage root-astragalus root particles for liver softening - Google Patents
Red sage root-astragalus root particles for liver softening Download PDFInfo
- Publication number
- CN1429607A CN1429607A CN 02160056 CN02160056A CN1429607A CN 1429607 A CN1429607 A CN 1429607A CN 02160056 CN02160056 CN 02160056 CN 02160056 A CN02160056 A CN 02160056A CN 1429607 A CN1429607 A CN 1429607A
- Authority
- CN
- China
- Prior art keywords
- radix
- liver
- blood
- root
- red sage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000007164 Salvia officinalis Species 0.000 title claims abstract description 14
- 229940107666 astragalus root Drugs 0.000 title claims abstract description 14
- 235000005412 red sage Nutrition 0.000 title claims abstract description 14
- 210000004185 liver Anatomy 0.000 title claims description 26
- 239000002245 particle Substances 0.000 title claims description 13
- 239000003814 drug Substances 0.000 claims abstract description 36
- 210000000582 semen Anatomy 0.000 claims description 9
- 239000009636 Huang Qi Substances 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- 235000003826 Artemisia Nutrition 0.000 claims description 7
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 7
- 244000030166 artemisia Species 0.000 claims description 7
- 235000009052 artemisia Nutrition 0.000 claims description 7
- 241000411851 herbal medicine Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000008187 granular material Substances 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 13
- 230000017531 blood circulation Effects 0.000 description 11
- 206010019668 Hepatic fibrosis Diseases 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 235000021286 stilbenes Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 102000002734 Collagen Type VI Human genes 0.000 description 1
- 108010043741 Collagen Type VI Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000010231 banlangen Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of granules for treating hepatism and hepatofibrosis is prepared from 6 Chinese medicinal materials including red sage root, astragalus root, peach kernel, red peony root, etc. in a certain proportion. Its advantages are high curative effect, quickly taking its effect and no toxic by-effect.
Description
Technical field
The present invention relates to a kind of Red sage root-astragalus root particles for liver softening, be applicable to treatment deficiency of both QI and YIN, stagnation of blood stasis and heat type hepatopathy.
Background technology
China has 1.2 hundred million hepatitis B virus carrierss and 50,000 hepatitis C patients approximately at present, liver puncture specimen pathological analysis shows that light-duty chronic hepatitis generation fibrosis person accounts for 62.6%, in, hepatic fibrosis person is taken place is 100% to severe person, various chronic hepatopathys move towards liver cirrhosis by Fibrotic development.Patient with liver cirrhosis accounts for the 4.3-14.2% of the total number of hospitalized of internal medicine, and its case fatality rate is only second to malignant tumor and occupies second in digestive system.If can block, alleviate and even reverse hepatic fibrosis, can improve the prognosis of hepatopathy to a great extent, improve patient's life quality and life-saving, modern medicine has become bright and clear to the hepatic fibrosis study of pathogenesis, and anti-hepatic fibrosis research is more active.Clinical Western medicine commonly used such as r-interferon, anti-hepatic fibrosis medicines such as colchicine suppress the synthetic or promotion degraded of collagen from different links, and clinical efficacy remains to be proved, and side effect is bigger, unsuitable prolonged application.
The clean injection of other Chinese patent medicine such as hepatitis, it is with the heat clearing away of Artemisia anethoicles Mattf function of gallbladder promoting, dries and removes the yellow monarch drug that is, minister is with Fructus Gardeniae, Radix Isatidis, bile paste resolving heat and reducing pathogenic fire, the tonneau three warmers, assistant with Radix Et Rhizoma Rhei, Radix Scutellariae purge heat removing blood stasis, cleanse the intestines and stomach, the tonneau stool cures mainly the damp-heat type jaundice.
Summary of the invention
Technical problem to be solved by this invention provides a kind ofly has therapeutical effect to hepatic fibrosis, body is increased the Red sage root-astragalus root particles for liver softening of immunocompetence.
The technical solution adopted for the present invention to solve the technical problems:
The present invention is made by Chinese herbal medicine, and it includes Radix Salviae Miltiorrhizae, the Radix Astragali, Semen Persicae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati, the Rhizoma Atractylodis Macrocephalae, and the ratio of weight and number of the above-mentioned medicine of respectively distinguishing the flavor of is: Radix Salviae Miltiorrhizae 4-10, Radix Astragali 2-8, Semen Persicae 1-5, Radix Paeoniae Rubra 1-6, Rhizoma Polygoni Cuspidati 1-7, Rhizoma Atractylodis Macrocephalae 1-6.
The present invention also includes Radix Angelicae Sinensis, Artemisia anethoicles Mattf, Caulis Spatholobi, Fructus Ligustri Lucidi, Fructus Schisandrae Chinensis, Radix Glycyrrhizae, and the ratio of weight and number of the above-mentioned medicine of respectively distinguishing the flavor of is: Radix Angelicae Sinensis 1-4, Artemisia anethoicles Mattf 1-5, Caulis Spatholobi 2-7, Fructus Ligustri Lucidi 1-5, Fructus Schisandrae Chinensis 1-5, Radix Glycyrrhizae 1-4.
Processing and fabricating method of the present invention following (is example with 12 flavor medicines):
Take by weighing the medicine of respectively distinguishing the flavor of by ratio requirement, get Radix Salviae Miltiorrhizae, the Rhizoma Atractylodis Macrocephalae, with 6 times of amount alcohol reflux 1.5 hours, filter, behind the decompression filtrate recycling ethanol, water liquid device is in addition collected; Medicinal residues and Radix Angelicae Sinensis, Rhizoma Polygoni Cuspidati, Fructus Ligustri Lucidi, Fructus Schisandrae Chinensis merge, and measure 75% alcohol reflux three times with 5 times respectively, and each 1 hour, filter, behind the decompression filtrate recycling ethanol, continue to be condensed into clear paste, concentrated solution device is in addition collected; Get all the other medicines such as Semen Persicae, Caulis Spatholobi again, add 12 times of water gagings respectively and decoct secondary, each 1.5 hours, filter, filtrate decompression is condensed into clear paste; Be blended into medicine concentrated solution such as above-mentioned Radix Angelicae Sinensis, Rhizoma Polygoni Cuspidati and Radix Salviae Miltiorrhizae, Rhizoma Atractylodis Macrocephalae water liquid, it is an amount of to add dextrin, stir evenly, and spray drying, dry powder adds protein sugar, dextrin is an amount of, mixing, granule is made in dry-pressing, promptly.
The present invention is based on understanding and the Therapeutic Principle of motherland's medical science to hepatic lesions, achieve with reference to modern pharmacological research, from motherland's medicine treasure-house, filter out the natural Chinese medicine of QI invigorating, YIN nourishing, blood circulation promoting and blood stasis dispelling, by the theory of Chinese medical science prescription, skim the cream off milk, reach the symptom of rapid alleviation and elimination hepatic fibrosis.
Treatment mechanism of the present invention is as follows:
Radix Salviae Miltiorrhizae can be changed the liver blood stasis, but promoting tissue regeneration by removing blood stasis again, the sweet temperature of the Radix Astragali is the panacea of QI invigorating, the key medicine of spleen reinforcing, week the row whole body, share with all blood circulation promoting medicines, promote all medicines, make that the prosperous blood of gas is capable, the stasis of blood is dispelled ruton and just do not hindered, two flavors are all monarch drug.The Semen Persicae blood stasis removing and clots absorbing, Radix Paeoniae Rubra is returned Liver Channel, is apt to away blood system, is longer than promoting blood circulation and cooling blood, and removing fire from the liver.Rhizoma Polygoni Cuspidati both can invigorate blood circulation loose clean, again can clearing away heat-damp and promoting diuresis, still can relieving constipation by purgation, be used for constipation with heat retention, join the loosening bowel to relieve constipation of Radix Angelicae Sinensis, Semen Persicae, blood circulation promoting and blood stasis dispelling, relieving accumulation of pathogens is logical to stagnate, and draws stagnant heat from just descending down, makes heresy outlet be arranged and non-impairment of YIN blood.Semen Persicae, Rhizoma Polygoni Cuspidati, Radix Paeoniae Rubra are joined Radix Salviae Miltiorrhizae, blood circulation promoting and dispersing pathogen accumulation, and broken stagnant blood note of the ancient Chinese knot, removing heat from blood and promoting blood circulation, superficial heat in the blood that disappears, promoting tissue regeneration by removing blood stasis is defended battalion and is passed unimpeded, and is used for the stagnant heat the liver rump, the opportunity of hitting, three medicines are ministerial drug altogether.Rhizoma Atractylodis Macrocephalae air making-up and spleen enlivening, dampness diuretic help the Radix Astragali to rouse oneself the spleen sun, and defeated cloth is precise and tiny, and the vital organs of the human body must be supported, and the liver QI and blood is full, and liver function begins to such an extent that recover, and also is ministerial drug.The sweet benefit of Radix Angelicae Sinensis is hot looses warm in nature logically, is the principal agent of blood-enriching and blood-promoting circulation, and with Radix Astragali mutual reinforcement between, QI and blood complements each other, the healthy energy of make suring reflex, gas foot blood is capable, blood is full of arteries and veins and fills, and blood stasis is removed to melting, be supporting vital QI and dispersing blood stasis also.The Caulis Spatholobi promoting the circulation of blood is enriched blood, and relaxing muscles and tendons and activating QI and blood in the collateral is joined Chinese angelica blood supplementing and invigorated blood circulation, and the dissipating blood stasis collateral dredging makes sea of blood abundance, and battalion defends unimpeded, and the stasis of blood goes channels logical also.The heat of Artemisia anethoicles Mattf liver heat removing gallbladder is held concurrently and is managed the strongly fragrant of liver and gall, makes damp and hot elimination, and stasis must be opened, and joins all blood circulation promoting medicines, makes blood stagnation in the liver person, with the capable cloth of failing of gas, joins Rhizoma Polygoni Cuspidati, becomes the removing summer-heat Liver Channel altogether, manages strongly fragrant agent of invigorating blood circulation.The special liver and kidney tonifying of Fructus Ligustri Lucidi merit, nourishing YIN and clearing away heat, the sour and astringent convergence of Fructus Schisandrae Chinensis, warm in nature and moisten, nourishing kidney is promoted the production of body fluid, and Fructus Ligustri Lucidi, Fructus Schisandrae Chinensis are with using, the merit multiplication of nourishing kidney, to consolidate lower-jiao Qi dysfunction, Fructus Schisandrae Chinensis, Fructus Ligustri Lucidi get the spleen invigorating yang invigorating of stilbene art, nourishing YIN activating QI and do not have the anxiety of mud diaphragm, stilbene art get Fructus Schisandrae Chinensis, Fructus Ligustri Lucidi the spleen strengthening and damp drying and do not have the fraud of impairment of YIN, four medicine nourishing spleen and kidney, moisturize mutual system, the spleen kidney must be transferred, set upright and get rid of evils, the above five tastes are adjuvant drug altogether.The Radix Glycyrrhizae tool relaxes the property of medicine, is in harmonious proportion the property of hundred medicines, with being to help to make.
Radix Salviae Miltiorrhizae, Semen Persicae, Radix Angelicae Sinensis, Radix Paeoniae Rubra, Caulis Spatholobi blood circulation promoting and blood stasis dispelling are to control in fact; The Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Ligustri Lucidi, Fructus Schisandrae Chinensis supplementing QI and nourishing YIN are to protect its void; Artemisia anethoicles Mattf, Rhizoma Polygoni Cuspidati clearing heat and expelling damp, with dispel its because of, all medicines share, the row of mend holding concurrently that disappears is supported and is just being dispelled long-pendingly, make stagnant heat and wash, the vim and vigour row of holding concurrently, healthy energy is from filling, then all diseases can be removed.
The pharmacodynamics test of Red sage root-astragalus root particles for liver softening shows: Red sage root-astragalus root particles for liver softening adds ethanol to carbon tetrachloride stimulates the rat liver fibrosis model that is caused to carry out the research of prevention and treatment, show and prevent 6 weeks of administration and treatment 4 weeks of administration all can obviously improve the general situation of rat, weight increase, reduction liver weigh, reduce liver body ratio; Reduce blood ALT, AST level, rising ALB, TP level are improved liver function; Reduce rat serum hyaluronic acid (HA), laminin (LN), blood III procollagen type (PCIII) and IV Collagen Type VI (IV.C) level; Rising to hydroxyproline content in the hepatic tissue has tangible reduction effect; Red sage root-astragalus root particles for liver softening improves significantly to rat carbon tetrachloride hepatic fibrosis mould hepatic pathology histological grade and V-G collagen fiber dyeing back pathology image analysis.Show that histopathology change degree alleviates, the total number of positive target reduces, the total number of positive target/statistics gross area reduces, the positive target gross area/statistics gross area reduces, reduce the Fibrotic area percentage of its pathology integration regulating liver-QI, the difference of significance is relatively arranged with model control group.
The acute toxicity test of Red sage root-astragalus root particles for liver softening shows: giving the mouse stomach Red sage root-astragalus root particles for liver softening in one day is 78.0g/kg, observe mice generally in order, observed seven days continuously, none death of animal, be equivalent to more than 303.3 times of clinical 70kg people's per kilogram of body weight consumption per day, this medicine low toxicity, safety are described.
The long term toxicity test of Red sage root-astragalus root particles for liver softening shows: give the 2.6g/kg Mus of rat oral gavage Red sage root-astragalus root particles for liver softening 15.4g/kg, 7.7g/kg heavy, be equivalent to 60 times, 30 times, 10 times of the clinical consumption per day of 70kg people, successive administration 180 days, observe the general situation of animal, test the 3rd, 6 month not, detect hematology, blood biochemical indexes respectively; And live respectively and kill 12 and 16 animals, detect the dirty body ratio and the histopathologic change of important organ.Remain 12 animals, carry out 60 day convalescent period and observe, multiple These parameters is not all found the toxic reaction that lose obvious toxic and side effects and secondary, back, illustrate this medicine intend the clinical medicine dose that adopts and the course of treatment safety, low toxicity.
Beneficial effect of the present invention is as follows: (1) this medicine need not decoct, the administration of taking after mixing it with water, and taking convenience facilitates patients.(2) all flavour of a drug are raw material with the crude drug all, have no side effect.Being suitable for the patient takes for a long time.(3) the treatment hepatic fibrosis is rapid-action, effect is strong, good effect.
The specific embodiment
Embodiments of the invention see the following form:
Annotate: wherein proportioning is a ratio of weight and number.
Claims (2)
1, a kind of Red sage root-astragalus root particles for liver softening of making by Chinese herbal medicine, it includes Radix Salviae Miltiorrhizae, the Radix Astragali, Semen Persicae, Radix Paeoniae Rubra, Rhizoma Polygoni Cuspidati, the Rhizoma Atractylodis Macrocephalae, and the ratio of weight and number of the above-mentioned medicine of respectively distinguishing the flavor of is: Radix Salviae Miltiorrhizae 4-10, Radix Astragali 2-8, Semen Persicae 1-5, Radix Paeoniae Rubra 1-6, Rhizoma Polygoni Cuspidati 1-7, Rhizoma Atractylodis Macrocephalae 1-6.
2, Red sage root-astragalus root particles for liver softening according to claim 1 is characterized in that it also includes Radix Angelicae Sinensis, Artemisia anethoicles Mattf, Caulis Spatholobi, Fructus Ligustri Lucidi, Fructus Schisandrae Chinensis, Radix Glycyrrhizae, and the ratio of weight and number of the above-mentioned medicine of respectively distinguishing the flavor of is: Radix Angelicae Sinensis 1-4, Artemisia anethoicles Mattf 1-5, Caulis Spatholobi 2-7, Fructus Ligustri Lucidi 1-5, Fructus Schisandrae Chinensis 1-5, Radix Glycyrrhizae 1-4.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02160056 CN1228070C (en) | 2002-12-27 | 2002-12-27 | Red sage root-astragalus root particles for liver softening |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02160056 CN1228070C (en) | 2002-12-27 | 2002-12-27 | Red sage root-astragalus root particles for liver softening |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1429607A true CN1429607A (en) | 2003-07-16 |
| CN1228070C CN1228070C (en) | 2005-11-23 |
Family
ID=4753392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02160056 Expired - Fee Related CN1228070C (en) | 2002-12-27 | 2002-12-27 | Red sage root-astragalus root particles for liver softening |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1228070C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101334386B (en) * | 2007-04-27 | 2012-07-11 | 上海现代中医药股份有限公司 | Determination method for plant medicine blood plasma amygdalin for strengthening the body resistance |
| CN104784278A (en) * | 2015-04-24 | 2015-07-22 | 淄博齐鼎立专利信息咨询有限公司 | Application of traditional Chinese medicine composition in preparing medicines for restraining cell proliferation of liver fibrosis |
-
2002
- 2002-12-27 CN CN 02160056 patent/CN1228070C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101334386B (en) * | 2007-04-27 | 2012-07-11 | 上海现代中医药股份有限公司 | Determination method for plant medicine blood plasma amygdalin for strengthening the body resistance |
| CN104784278A (en) * | 2015-04-24 | 2015-07-22 | 淄博齐鼎立专利信息咨询有限公司 | Application of traditional Chinese medicine composition in preparing medicines for restraining cell proliferation of liver fibrosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1228070C (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100518807C (en) | A Medicine for treatment of ascites due to cirrhosis | |
| CN104042988A (en) | Preparation for treating eczema and preparation method thereof | |
| CN102430079B (en) | Traditional Chinese medicine composite for treating stranguria | |
| CN103007191A (en) | Chinese medicinal composition for treating jaundice | |
| CN103055285A (en) | Traditional Chinese medicine for treating forepart hepetocirrhosis and preparation method thereof | |
| CN104225166A (en) | Chinese medicine composition for treating amenorrhea and preparation method thereof | |
| CN104524159A (en) | Pharmaceutical composition for treating hyperplasia of mammary glands | |
| CN101428114B (en) | Medicament for treating chronic hepatitis B, cirrhosis and liver ascites | |
| CN1228070C (en) | Red sage root-astragalus root particles for liver softening | |
| CN101940758B (en) | Traditional Chinese medicinal composition for treating liver diseases, preparation method thereof and application thereof | |
| CN101264218A (en) | Medicaments assembly for clearing heat and removing dampness, smoothing liver and invigorating spleen and preparation thereof | |
| CN104721644A (en) | Traditional Chinese medicine preparation for knee osteoarthritis and preparation method of traditional Chinese medicine preparation | |
| CN103169894B (en) | Traditional Chinese medicine composition for treating proteinuria | |
| CN102988632B (en) | Chinese medicinal composition for treating oedematous | |
| CN105343313A (en) | Traditional Chinese medicinal composition for treating senile skin pruritus and preparation method of traditional Chinese medicinal composition | |
| CN105456924A (en) | Traditional Chinese medicine preparation containing Folium Artemisiae Argyi and having functions of promoting circulation and removing stasis and preparation method thereof | |
| CN104587281A (en) | Spleen invigoration and diuresis promoting traditional Chinese medicine composition for treating cirrhosis and preparation | |
| CN104840865A (en) | Traditional Chinese medicine preparation for treating gouty arthritis | |
| CN103263580A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN103230475B (en) | One treats psoriatic medicine | |
| CN100348236C (en) | Medicine for treating diabetes | |
| CN102335243B (en) | Chinese medicinal composition for treating icteric hepatitis | |
| CN102166303B (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis | |
| CN1194860A (en) | Agentia for improving genitality and producing process thereof | |
| CN1326555C (en) | Chinese medicinal powder preparation for treating hepatic ascites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20051123 Termination date: 20111227 |